Beatrice J. Edwards

TL;DR: Erythropoiesis-stimulating agent administration to patients with cancer is associated with increased risks of venous thromboembolism (VTE) and mortality, and these findings raise concern about the safety of ESA administration to Patients with cancer.

TL;DR: The ASBMR Task Force suggests that after 5 years of oral BP or 3 years of intravenous BP, reassessment of risk should be considered, and in women at high risk, older women, those with a low hip T-score or high fracture risk score, or who fracture on therapy, continuation of treatment for up to 10 years (oral) or 6 years (intravenous), with periodic evaluation, should be consideration.

TL;DR: A narrative review of osteonecrosis of the jaw in patients with low bone mass receiving treatment with antiresorptive agents is based on an appraisal of the literature as discussed by the authors.

TL;DR: The findings identify new predictor variables for risk of falling that underscore the importance of dynamic balance recovery performance through ML stepping in relation to neuromusculoskeletal factors contributing to lateral balance stability.

TL;DR: For patients receiving bisphosphonate therapy, the risk of developing bisph phosphonate-associated osteonecrosis of the jaw apparently remains low and it newly concludes that current screening and diagnostic tests are unreliable for predicting a patient'srisk of developing the condition.